Ads
related to: celebrex kidney problems in women over 60- See Treatment Results
Help Relieve Your RA Symptoms
With A Once-Daily Oral Pill.
- Find A Rheumatologist
Find A Rheumatologist Near You.
Set Goals For RA Treatment.
- Discover An RA Treatment
Still Experiencing RA Symptoms?
A Treatment Plan Change May Help.
- Injection-Free Treatment
RA TNF Blocker Didn't Work For You?
See How A JAK Inhibitor May Help.
- See Treatment Results
Search results
Results From The WOW.Com Content Network
Celecoxib, sold under the brand name Celebrex among others, is a COX-2 inhibitor and nonsteroidal anti-inflammatory drug (NSAID). [7] It is used to treat the pain and inflammation in osteoarthritis, acute pain in adults, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, painful menstruation, and juvenile rheumatoid arthritis. [7]
Celebrex (and other brand names for celecoxib) was introduced in 1999 and rapidly became the most frequently prescribed new drug in the United States. By October 2000, its US sales exceeded 100 million prescriptions per year for $3 billion, and was still rising. Sales of Celebrex alone reached $3.1 billion in 2001.
The widespread use of NSAIDs has meant that the adverse effects of these drugs have become increasingly common. Use of NSAIDs increases risk of a range of gastrointestinal (GI) problems, kidney disease and adverse cardiovascular events. [40] [41] As commonly used for post-operative pain, there is evidence of increased risk of kidney ...
[5] [6] It took less than eight years to develop and market the first COX-2 inhibitor, with Celebrex launched in December 1998 and Vioxx launched in May 1999. [ 7 ] [ 8 ] Celecoxib and other COX-2 selective inhibitors, valdecoxib , parecoxib , and mavacoxib , were discovered by a team at the Searle division of Monsanto led by John Talley .
The therapeutic recommended dosages were 12.5, 25, and 50 mg with an approximate bioavailability of 93%. [12] [13] [14] Rofecoxib crossed the placenta and blood–brain barrier, [12] [13] [15] and took 1–3 hours to reach peak plasma concentration with an effective half-life (based on steady-state levels) around 17 hours.
Novo Nordisk's Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight and obese people in a large study, according to a new analysis the Danish drugmaker published on Saturday.
Ad
related to: celebrex kidney problems in women over 60